DelveInsight’s “Presbyopia – Pipeline Insight, 2026” report provides comprehensive insights about 10+ companies developing several pipeline drugs in the Presbyopia pipeline landscape. It covers the Presbyopia pipeline drug profiles, including clinical and nonclinical stage products, along with therapeutics assessment by product type, stage, route of administration, and molecule type, and further highlights inactive pipeline products in this space.
Explore the latest breakthroughs in the Presbyopia treatment landscape. Learn more about the evolving Presbyopia pipeline today @ https://www.delveinsight.com/sample-request/presbyopia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr
Key Takeaways from the Presbyopia Pipeline Report
-
In February 2026, Viatris Inc. (Nasdaq: VTRS) announced that the Food and Drug Administration (FDA) accepted for review the supplemental New Drug Application (sNDA) for MR-141 (phentolamine ophthalmic solution 0.75%) for the treatment of presbyopia. The FDA has assigned a PDUFA goal date of October 17, 2026.
-
In January 2026, Yuvezzi (carbachol and brimonidine tartrate) received approval as an ophthalmic solution for the treatment of presbyopia.
-
In October 2024, the FDA accepted the New Drug Application (NDA) for LNZ100 (aceclidine eye drop) submitted by LENZ Therapeutics for the treatment of presbyopia — a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States. The FDA assigned a PDUFA target action date of August 8, 2025 for LNZ100.
-
DelveInsight’s Presbyopia Pipeline Insight report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Presbyopia treatment.
-
The leading Presbyopia companies include Glaukos Corporation, Orasis Pharmaceuticals, Novartis, Cellix Bio, Visus Therapeutics, AbbVie, Vyluma, Lenz Therapeutics, Ocuphire Pharma, JIXING Pharmaceuticals, Eyenovia, and others.
-
Promising Presbyopia therapies include LX-OPH-162, Research programme, STN 1013600, GLK-302, Nyxol, VTI-001, LNZ100, MicroLine (Pilocarpine Ophthalmic), CSF-1 (PresbiDrops), VT-101 (Brimochol), AGN-241622, and others.
Download for updates and the latest revolution in Presbyopia care @ Presbyopia Clinical Trials Assessment
Presbyopia Emerging Drugs Profile
LNZ100: Lenz Therapeutics
LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine, a selective muscarinic receptor agonist. It works by constricting the pupil, creating a pinhole effect that improves near vision. Unlike other pupil-constricting agents, aceclidine has a unique mechanism of action that decouples the miotic effect from the stimulation of the ciliary muscle, reducing the risk of myopic shift and accompanying brow ache. This allows LNZ100 to provide a broad patient population with a long-lasting and efficient treatment for presbyopia, a condition characterized by the gradual hardening of the lens and decline in near vision with age. LNZ100 is currently in Phase III stage of its clinical trial for the treatment of presbyopia.
GLK-302: Glaukos Corporation
GLK-302 is an investigational therapy being developed by Glaukos Corporation for the treatment of presbyopia. The drug is currently being evaluated in a Phase II clinical trial as part of the company’s ophthalmic pipeline, with Glaukos actively advancing its presbyopia treatment program toward later-stage development.
For more information on the Presbyopia Emerging Drugs Profile, download DelveInsight’s comprehensive Presbyopia Pipeline Insight report.
The Presbyopia Pipeline Report Provides
-
Detailed insights about companies developing therapies for Presbyopia, with aggregate therapies developed by each company.
-
Different therapeutic candidates, segmented into early-stage, mid-stage, and late-stage of development for Presbyopia treatment.
-
Presbyopia companies that are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
Presbyopia drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company–company and company–academia), licensing agreements, and financing details for future advancement of the Presbyopia market.
Learn more about Presbyopia drug opportunities in our comprehensive report @ Presbyopia Unmet Needs
Presbyopia Companies
There are 10+ key companies, such as Glaukos Corporation, Orasis Pharmaceuticals, Novartis, Cellix Bio, Visus Therapeutics, AbbVie, Vyluma, Lenz Therapeutics, Ocuphire Pharma, JIXING Pharmaceuticals, Eyenovia, and others, developing therapies for Presbyopia, with Lenz Therapeutics having its Presbyopia drug candidate in the most advanced Phase III stage.
DelveInsight’s Presbyopia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:
-
Oral
-
Intravenous
-
Subcutaneous
-
Parenteral
-
Topical
Presbyopia products have been categorized under various molecule types such as:
-
Recombinant fusion proteins
-
Small molecule
-
Monoclonal antibody
-
Peptide
-
Polymer
-
Gene therapy
Discover the latest advancements in Presbyopia treatment @ Presbyopia Market Drivers and Barriers, and Future Perspectives
Scope of the Presbyopia Pipeline Report
-
Coverage: Global
-
Presbyopia Companies: Glaukos Corporation, Orasis Pharmaceuticals, Novartis, Cellix Bio, Visus Therapeutics, AbbVie, Vyluma, Lenz Therapeutics, Ocuphire Pharma, JIXING Pharmaceuticals, Eyenovia, and others.
-
Presbyopia Therapies: LX-OPH-162, Research programme, STN 1013600, GLK-302, Nyxol, VTI-001, LNZ100, MicroLine (Pilocarpine Ophthalmic), CSF-1 (PresbiDrops), VT-101 (Brimochol), AGN-241622, and others.
-
Presbyopia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
-
Presbyopia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Table of Contents
1. Introduction
2. Executive Summary
3. Presbyopia: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Presbyopia – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Mid Stage Products (Phase II)
9. Early Stage Products (Phase I)
10. Preclinical and Discovery Stage Products
11. Inactive Products
12. Presbyopia Key Companies
13. Presbyopia Key Products
14. Presbyopia Unmet Needs
15. Presbyopia Market Drivers and Barriers
16. Presbyopia Future Perspectives and Conclusion
17. Presbyopia Analyst Views
18. Appendix
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services
